CD44 and cancer: pRGO modified with CD44 targeting ligand hyaluronic acid (HA) was used in combination with DOX-loaded mesoporous silica (MS) (pRGO@MS-HA) to generate both pH and NIR-triggered DOX release from the multifunctional nanosystems, showing excellent combined effect in multimodal cancer therapy.